Dear Friend,

In these times of COVID-19, climate chaos and elections, independent news is more important than ever. You turn to Democracy Now! because you trust that when we're reporting on the pandemic or the uprisings against police brutality—or the climate crisis—our coverage is not brought to you by the fossil fuel, insurance or weapons industries or Big Pharma. We count on YOU to make our work possible. If everyone who visits our website gave just $8, we could cover our operating costs for 2021. Really—that’s all it would take. And today, a generous supporter will DOUBLE your donation to Democracy Now!, meaning your gift will go twice as far. This is a challenging time for us all, but if you're able to make a donation, please do so today. Stay safe, wear a mask and thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


Oxford Vaccine Shows Promising Results as New Data Suggests Antibodies in Recovered Cases Don’t Last

HeadlineOct 27, 2020

In medical news, scientists at AstraZeneca said Monday an experimental vaccine being developed at Oxford University in Britain has shown promising results as the vaccine has triggered an immune response in both younger and older patients. Meanwhile, researchers at Imperial College in London found the number of people testing positive for COVID-19 antibodies has fallen by 26% between June and September, suggesting immunity fades rapidly and people who have recovered can be reinfected.

In more medical news, drug maker Eli Lilly said Monday its antibody treatment was ineffective on hospitalized patients with advanced cases and that a government-sponsored trial would stop administering the drug to new patients.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation